Updates in the treatment of basal/triple-negative breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 25, Issue 1, 2013, Pages 40-48

  Shastry, Mythili ^a   Yardley, Denise A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

antiangiogenesis; basal like breast cancer; polyadenosine diphosphate ribose polymerase; targeted therapies; triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BUPARLISIB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN KINASE B; TAXANE DERIVATIVE; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VELIPARIB;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG SAFETY; GENE EXPRESSION PROFILING; GENE TARGETING; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; CYTOTOXINS; DNA DAMAGE; FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84873089796     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32835c1633     Document Type: Review

References (71)

1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70.
2. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68.
3. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14:1368-1376.
4. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the 'triple-negative' phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116:317-328.
5. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20:1913-1927.
6. Gelmon K, Dent R, Mackey JR, et al. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012; 23:2223-2234.
7. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17:1082-1089.
8. Vollebergh MA, Lips EH, Nederlof PM, et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011; 22:1561-1570.
9. Oonk AMM, van Rijn C, Smits MM, et al. Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol 2012; 23:2301-2305.
10. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
11. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5:5-23.
12. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2011; 16 (Suppl 1):61-70.
13. Lachapelle J, Foulkes WD. Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol 2011; 18:161-164.
14. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-1948.
15. Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012; 4:195-210.
16. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27:1168-1176.
17. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124:133-140.
18. Martin M, Segui MA, Anton A, et al. Adjuvant docetaxel for high-risk, nodenegative breast cancer. N Engl J Med 2010; 363:2200-2210.
19. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678-5685.
20. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329-2334.
21. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-1281.
22. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366:2438-2441.
23. Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27:526-534.
24. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010; 121:261-271.
25. Dumontet C, Jordan MA, Lee FFY. Ixabepilone: targeting bIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009; 8: 17-25.
26. Horak CE, Lee FY, Xu L, et al. High beta-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. ASCO Meeting Abstracts; 8 June 2009; 27(15S): 3587.
27. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012; 30:11-18.
28. O'Shaughnessy J, Devchand P, Stokoe C. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide followed by docetaxel with or without capecitabine in high-risk early breast cancer. SABCS 2010; 2010:Abstract S4-S2.
29. Zelnak AB, Harichand-Herdt S, StybloTM, et al. Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers. J Clin Oncol 2011; 29(Suppl):abstr 1118.
30. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28:1145-1153.
31. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triplenegative breast cancer. Ann Oncol 2008; 19:1847-1852.
32. Alba E, Chacon JI, Lluch A, et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study. J Clin Oncol 2011; 29(Suppl):abstr 1015.
33. Isakoff SJ, Goss PE, Mayer EL, et al. TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 2011; 29(Suppl):abstr 1025.
34. Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, nonrandomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012; 14:R110.
35. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-214.
36. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29(Suppl):abstr 1007.
37. Llombart A, Lluch A, Villanueva C, et al. SOLTI NeoPARP: a phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). J Clin Oncol 2012; 30(Suppl):abstr 1011.
38. Patel AG,De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADPRibose) polymerase in vitro. Clin Cancer Res 2012; 18:1655-1662.
39. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteinecontaining proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18:510-523.
40. Dent RA, Lindeman GJ, Clemons M, et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first-or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010; 28 (Suppl 15):1018.
41. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol 2011; 12:852-861.
42. Perez EA, Hillman DW, Mailliard JA, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004; 22:2849-2855.
43. von Hoff DD, Jameson GS, Borad MJ, et al. First phase 1 trial of NKTR-102 (Peg-Irinotecan) reveals early evidence of broad antitumor activity in three different schedules. EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics' Meeting; 21-24 October 2008; Geneva, Switzerland. Poster no. 595.
44. Awada A, Chan S, Jerusalem GHM, et al. Significant antitumor activity in a randomized phase 2 study comparing 2 schedules of Nktr-102 in patients (Pts) with metastatic breast cancer (MBC). Ann Oncol 2012; 23(Suppl 2):abstract 101P.
45. Cynthia RC, Osborne JOS, Holmes FA, et al. Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC). J Clin Oncol 2012; 30(Suppl):abstr 1017.
46. Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20:1639-1646.
47. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
48. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-3247.
49. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252-1260.
50. O'Shaughnessy J, Romieu G, Dieras V, et al. Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2011; 70(Suppl 24):P6-12-03.
51. Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012; 133:1067-1075.
52. Brufsky AM, Hurvitz SA, Perez EA, et al. Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). ASCO Meeting Abstracts; 18 September 2012; 30(Suppl 27):100.
53. Thomssen C, Pierga JY, Pritchard KI, et al. First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology 2012; 82:218-227.
54. Schneeweiss A, Foerster F, Hollburg W, et al. Bevacizumab (Bev) combined with paclitaxel (Pac) as first-line therapy for metastatic triple-negative breast cancer (TNBC): analysis of 147 patients (pts) treated in routine oncology practice in Germany. Eur J Cancer 2011; 47 (Suppl 1):S352.
55. Bear HD, Tang G, Rastogi P, et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011; 29(Suppl 18):LBA1005.
56. Gerber B, Eidtmann H, Rezai M, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: secondary endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 2011; 29 (Suppl 15):1006.
57. Earl HM, Blenkinsop C, Grybowicz L, et al. ARTemis: randomized trial with neoadjuvant chemotherapy for patients with early breast cancer. J Clin Oncol 2012; 30 (Suppl 15):TS1144.
58. Tan AR, Buyse ME, Rastogi P, et al. NSAB FB-6: phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC). J Clin Oncol 2012; 30 (Suppl 15):1025.
59. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-5374.
60. O'Shaughnessy J, Weckstein D, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106 (Suppl 1):S32; Abstract 308.
61. Baselga J, Stemmer S, Pego A, et al. Cetuximab \+ cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triplenegative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2011; 70(Suppl 24):PD01-01.
62. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase ii study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615-2623.
63. Nabholtz J-M, Weber B, Gligorov J, et al. Panitumumab in combination with FEC 100 (5-fluorouracile, epirubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple negative breast cancer (TNBC): final results of a multicentre neoadjuvant pilot phase II study. Cancer Res 2012; 71(Suppl 24):P3-14-01.
64. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basaltype/' triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105:319-326.
65. Rimawi M, Rodriguez A, Yang W, et al. A phase II preoperative study of dasatinib, a multi-targeted tyrosine kinase inhibitor, in locally advanced 'triple-negative' breast cancer patients. Cancer Res 2012; 71(Suppl 24): P3-14-09.
66. Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single agent in triplenegative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17:6905-6913.
67. Gucalp A, Tolaney SM, Isakoff SJ, et al. Targeting the androgen receptor (AR) in women with AR\+ ER-/PR-metastatic breast cancer (MBC). ASCO Meeting Abstracts; 30 May 2012; 30(Suppl 15):1006.
68. Dedeurwaerder S, Fumagalli D, Fuks F. Unravelling the epigenomic dimension of breast cancers. Curr Opin Oncol 2011; 23:559-565.
69. Grushko TA, Nwachukwu C, Charoenthammaraksa S, et al. Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. ASCO Meeting Abstracts; 14 June 2010; 28(Suppl 15):10510.
70. Tate CR, Rhodes LV, Segar HC, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 2012; 14:R79.
71. Sharma D, Knight BB, Yacoub R, et al. Using epigenetic reprogramming to target triple-negative breast cancer. ASCO Meeting Abstracts; 8 June 2009; 27(15S):e14565.